CD70-CART（Hrain）

抗人CD70 T细胞（恒润达生生物）

Report date: 2023/07/18 14:44:04

Base Information

Drug NameCD70-CART（Hrain）
Drug Alias Name抗人CD70 T细胞注射液（恒润达生生物）HR010HR-010
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD70T lymphocyte replacements
TargetsCD70 antigen
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHrain Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHrain Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Renal Cell
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A